Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
BiohackingLongevity supplement brands have been growing — but Wonderfeel’s 2026 Inc. 5000 ranking makes the scale of that growth hard to ignore.
What Happened
Wonderfeel secured the top biotech position on the 2026 Inc. 5000 list, ranking No. 65 overall with a 4,235% three-year revenue increase. The figure places the company in the top 1.3% of honorees and No. 12 among California-based private companies on the list.
The company’s flagship product is Youngr™ NMN, an NMN formula developed by Dr. Andrew Salzman and validated in the International Journal of Nutrition and Food Sciences. Their recent product expansion — including ChocoCreatin™, a zero-sugar chocolate bar containing 4 grams of creatine monohydrate — reflects a strategic shift toward formats that lower the compliance barrier for daily longevity protocols. The company describes its next direction as moving beyond nutraceuticals into advanced cellular diagnostics.
Why It Matters
NAD+ is not a new category. NMN and NR (nicotinamide riboside) supplements have been commercially available for nearly a decade, and the scientific literature on their effects — NAD+ precursors appear to raise NAD+ levels in humans, but clinical evidence for functional longevity outcomes remains early-stage — has not fundamentally changed. What has changed is consumer willingness to act on the research before it’s definitive.
The Wonderfeel growth curve reflects a demand pattern that’s consistent with the broader longevity supplement market: early-adopter buyers who were primarily biohackers and performance athletes in 2020 have been joined by a much larger population of health-conscious consumers acting on mainstream longevity coverage. Peter Attia’s work, Huberman Lab, and the growing direct-to-consumer longevity clinic sector have collectively moved NAD+ supplementation from niche protocol to normalized practice for a segment of the general population.
The vertical expansion into creatine delivery formats is instructive. Creatine has robust clinical evidence across muscle function, cognitive performance, and aging markers, and it occupies a higher-confidence tier than NMN in the evidence hierarchy. Bundling it into a consumer-friendly chocolate format signals that Wonderfeel is targeting mainstream adoption, not just committed biohackers.
The So What
The Wonderfeel Inc. 5000 result is evidence of a broader transition: the longevity supplement market is past the point where growth is driven by early adopters alone. Companies that can combine credible formulations with accessible formats are finding significantly larger addressable markets than the core biohacker audience. For practitioners tracking the NAD+ category, the competitive landscape in NMN is now dense enough that differentiation is increasingly about delivery and brand trust rather than the ingredient itself. Cellular diagnostics — Wonderfeel’s stated next direction — represents the logical upstream move: connecting supplement protocols to measurable biological markers is where the category’s durable value is likely to migrate.
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →